Breakfast News: A Conversation With Moderna's CEO

This August, Moderna (MRNA -1.25%) and Merck (MRK -1.34%) reported that their personalized cancer vaccine, intismeran autogene, cut the risk of melanoma recurrence after surgery when added to Keytruda. The result came from a phase 3 trial, the large final-stage study regulators lean on for approval.